ReviewWorld journal of critical care medicine2025
Methylene blue in the critical care setting.
Review in World journal of critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Administration of Methylene Blue to Facilitate the Management of Post-Cardiac Arrest Refractory Shock.JACC. Case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methylene blue (MB) is a versatile medicine with a long history of use in various medical applications, including dye, antiseptic, and treatment for methemoglobinemia. It has a role in vasoconstriction, methemoglobin reduction, inhibition of guanylate cyclase, and anti-inflammatory effects. We reviewed PubMed and Google Scholar literature for relevant studies on MB in intensive care unit (ICU). We created search criteria using a combination of free text words, including MB, critical care, intensive care, sepsis, surgery, pharmacokinetics, and pharmacodynamics. Relevant articles published in the English language were analyzed and incorporated. MB has been used in managing patients with refractory shock, including septic shock, vasoplegic shock, surgical patients, and some instances of drug-induced hypotension. In conclusion, MB in the ICU is a promising medication for sepsis and vasoplegic shock. Further research with randomized trials on its long-term safety in the ICU, time of initiation, dose, and duration is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.